TL;DR
Lichen sclerosus (LS) usually affects the genital area, but around 15 percent of patients also develop extragenital patches on chest, neck, shoulders, or wrists. These porcelain-white, slightly atrophic plaques need barrier protection, sun avoidance, and prescription-grade clobetasol from a dermatologist. Skincare supports. It does not replace.
If you have a lichen sclerosus diagnosis, most of what is written for you is about the genital area, and rightly so, that is where the disease causes the most harm. But the ivory, slightly crinkly patches that show up on the upper back or sternum deserve their own conversation, because the skincare aisle is full of things that will make them worse.
What it is and how it presents outside the genitals
Extragenital LS shows up as well-defined white plaques, often with a faint pink or purple rim, sometimes with follicular plugging that gives a stippled surface. The skin is thinner than the surrounding area and can look slightly waxy. Patches are usually painless but can itch. Common locations: upper back, neckline, shoulders, breasts, inner wrists, occasionally the thighs. They are not contagious. They tend to grow slowly over months.
Diagnosis is clinical, often confirmed by biopsy. Because extragenital LS is rarer than genital LS, many patients are first told they have vitiligo, morphea, or scarring from a chemical burn. The two conditions can coexist; if you have genital LS and a new white patch elsewhere, mention it.
Why it happens
LS is autoimmune. T cells attack the dermo-epidermal junction; elastic and collagen fibres degenerate; sclerosis develops. Roughly 20 percent of patients have a personal or family history of other autoimmune disease, typically thyroid disease, alopecia areata, or vitiligo. The Koebner phenomenon matters here: trauma to skin (a friction point, a tight strap, a scratched mosquito bite) can seed new lesions. This is why skincare matters even though it cannot cure.
What actually helps
The medical anchor is high-potency topical steroid. Clobetasol propionate 0.05 percent ointment, applied to extragenital plaques daily for six to twelve weeks, then tapered to two to three times weekly, is the published standard. Tacrolimus 0.1 percent is a steroid-sparing option for longer maintenance. Neither is something to self-prescribe.
Supportive skincare is about not adding insult. Daily SPF 50 is non-negotiable; UV worsens both the immune attack and the dyspigmentation. Cleanse with a fragrance-free, sulfate-free wash. BioCell Renewal Cream sits well over treated areas once the prescription steroid has been absorbed; the ceramide and squalane base reinforces a thinning barrier without acids or fragrance. Squalane works particularly well on the slightly waxy texture of extragenital LS because it absorbs without leaving residue that could trap friction.
Niacinamide 5 percent helps with the post-inflammatory pinkness around plaques. Barrier-repair routines are useful framing. Cotton, not synthetic, against affected skin. Loose clothing where bra straps or seams cross plaques.
What does not work and may harm
Strong acids. AHAs, BHAs, glycolic peels. They thin already-thin skin. Retinoids on the plaques themselves. Aggressive scrubs. Hot water. Strong fragrances. Bleaching creams (the patches are not pigment loss, they are sclerosis, and trying to “match” them with hydroquinone elsewhere does nothing useful). DIY essential oil rubs, especially undiluted tea tree, which sting more than they soothe.
The other thing that does not help is online forums recommending coconut oil as a treatment. It is bland, it is occlusive, it is fine as a body moisturiser if you tolerate it, but it has no impact on the underlying autoimmune process.
When to see a dermatologist
Any new white patch with the described texture deserves prompt evaluation, especially if you have genital LS already. The extragenital form has a lower cancer risk than genital LS, but it still requires monitoring. Annual follow-up is standard. Biopsy is sometimes needed to differentiate from morphea, which has a different treatment ladder. A derm who knows LS will also screen for thyroid disease and other autoimmune comorbidities, which is the kind of joined-up care this condition deserves.
A real-numbers anchor
A 2018 British Journal of Dermatology study following 327 LS patients reported extragenital involvement in 15.7 percent, with clobetasol clearance of active inflammation in 78 percent of treated patches at 12 weeks, though residual pigment and texture changes persisted long-term in over half.
FAQ
Will the white patches ever go away? Active inflammation can be quieted, but the textural and pigment changes often persist. Early treatment minimises further spread.
Is sun exposure helpful or harmful? Harmful. UV both triggers Koebner-spread and increases skin cancer risk on already-thinned skin.
Can I exfoliate around the patches? Around, yes, gently. On the patches, no.
Is LS linked to vitiligo? Both are autoimmune and can co-occur, but they are distinct. Vitiligo is loss of pigment; LS is sclerosis with secondary depigmentation.
Should I avoid hormones? No firm evidence either way for extragenital disease. Menopause sometimes coincides with diagnosis, which is correlation more than causation.
More reading: the barrier-damage tag.
Sources
Kirtschig G et al. Evidence-based S3 guideline on the treatment of lichen sclerosus. Journal of the European Academy of Dermatology and Venereology, 2015. Powell J, Wojnarowska F. Lichen sclerosus. British Journal of Dermatology, 2018. AAD.org/” rel=”noopener” target=”_blank”>American Academy of Dermatology. Lichen sclerosus patient guidance, 2023.